Janssen Collaborates with Genmab For HexaBody-CD38

By Jasmine Kalsi & Michelle Liu

Pharma Deals Review: Vol 2019 Issue 6 (Table of Contents)

Published: 18 Jun-2019

DOI: 10.3833/pdr.v2019.i6.2435     ISSN: 1756-7874

Section: Research & Development



Complementing its growing haematology franchise, Janssen Biotech has entered into a global license and option agreement with Genmab to develop and commercialise its preclinical candidate, HexaBody-CD38...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details